Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934
(Amendment No. 5)*

 

Aileron Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

00887A 105

(CUSIP Number)

 

Bart Dzikowski

Secretary of the Board

Novartis Bioventures Ltd.

Lichtstrasse 35

CH-4056 Basel, Switzerland

+41 61 324 3714

 (Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

April 9, 2020

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

 

*

The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of section 18 of the Securities Exchange Act of 1934, as amended (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 0087A 105

Schedule 13D

 

1.	Names of reporting persons	Novartis Bioventures Ltd.
2.	Check the appropriate box if a member of a group	(a)           o (b)           o
3.	SEC use only
4.	Source of funds (see instructions)	WC
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	o
6.	Citizenship or place of organization	Switzerland
Number of shares beneficially owned by each reporting person with:
7.	Sole voting power	0
8.	Shared voting power	1,572,285
9.	Sole dispositive power	0
10.	Shared dispositive power	1,572,285
11.	Aggregate amount beneficially owned by each reporting person	1,572,285
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions)	o
13.	Percent of class represented by amount in Row (11)	5.65% (1)
14.	Type of reporting person (see instructions)	CO

 

(1)         Based on 27,810,358 shares of Common Stock outstanding as of March 20, 2020, as reported in the Issuers annual report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 30, 2020.

 

2

 

CUSIP No. 0087A 105

Schedule 13D

 

1.	Names of reporting persons	Novartis AG
2.	Check the appropriate box if a member of a group	(a)           o (b)           o
3.	SEC use only
4.	Source of funds (see instructions)	WC
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	o
6.	Citizenship or place of organization	Switzerland
Number of shares beneficially owned by each reporting person with:
7.	Sole voting power	0
8.	Shared voting power	1,572,285
9.	Sole dispositive power	0
10.	Shared dispositive power	1,572,285
11.	Aggregate amount beneficially owned by each reporting person	1,572,285
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions)	o
13.	Percent of class represented by amount in Row (11)	5.65% (1)
14.	Type of reporting person (see instructions)	CO

 

(1)         Based on 27,810,358 shares of Common Stock outstanding as of March 20, 2020, as reported in the Issuers annual report on Form 10-K filed with the SEC on March 30, 2020.

 

3

 

CUSIP No. 0087A 105

Schedule 13D

 

Item 1.   Security and Issuer.

 

This Amendment No. 5 (the Amendment) to Schedule 13D amends the Schedule 13D filed by the Reporting Persons (defined below) with the SEC on July 5, 2017, as previously amended on August 22, 2018,  March 18, 2019, April 3, 2019 and March 18, 2020 (the Original Schedule 13D and, together with the Amendment, the Schedule 13D) and relates to the common stock, par value $0.001 per share (the Common Stock), of Aileron Therapeutics, Inc., a Delaware corporation (the Issuer).  The address of the Issuers principal executive office is 490 Arsenal Way, Watertown, MA 02472.

 

As a result of the open market sales reported in Item 5(c) of this Amendment, the percentage of outstanding shares of Common Stock that the Reporting Persons may be deemed to beneficially own was reduced by more than one percent of the Issuers shares of Common Stock outstanding since the filing of the Original Schedule 13D.

 

Except as otherwise described herein, the information contained in the Original Schedule 13D remains in effect. Capitalized terms used but not defined in this Amendment shall have the respective meanings set forth with respect thereto in the Original Schedule 13D.

 

Item 2.   Identity and Background.

 

No changes.

 

Item 3.   Source and Amounts of Funds or Other Consideration.

 

No changes.

 

Item 4.   Purpose of Transaction.

 

The information set forth in Item 5(c) of this Amendment is incorporated herein by reference. Otherwise, there are no changes to the disclosure provided under this Item 4 in the Original Schedule 13D.

 

Item 5.   Interest in Securities of the Issuer.

 

(a)          As of the date hereof, the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Act, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of 1,572,285 shares of Common Stock. NBV is a wholly-owned indirect subsidiary of Novartis.  Based on 27,810,358 shares of Common Stock outstanding as of March 20, 2020, as reported in the Issuers annual report on Form 10-K filed with the SEC on March 30, 2020, the Common Stock held by the Reporting Persons constitutes 5.65% of the outstanding shares of Common Stock of the Issuer.

 

(b)           With respect to the number of shares of Common Stock as to which each Reporting Person has:

 

(i)            sole power to vote or to direct the vote with respect to such shares of Common Stock, please see row 7 of the applicable cover sheet to this Amendment for such Reporting Person;

 

(ii)           shared power to vote or to direct the vote with respect to such shares of Common Stock, please see row 8 of the applicable cover sheet to this Amendment for such Reporting Person;

 

(iii)          sole power to dispose or direct the disposition of such shares of Common Stock, please see row 9 of the applicable cover sheet to this Amendment for such Reporting Person; and

 

(iv)          shared power to dispose or to direct the disposition of such shares of Common Stock, please see row 10 of the applicable cover sheet to this Amendment for such Reporting Person.

 

(c)           Other than the open market sales referred to below or previously reported in the Original Schedule 13D, none of (i) the Reporting Persons or, (ii) to the Reporting Persons knowledge, the persons set forth on Schedule I hereto has effected any transaction in the Common Stock during the past 60 days.

 

On April 9, 2020, the Reporting Persons sold 55,230 shares of Common Stock at a weighted average price of $0.43 per share (price range: $0.40 $0.47).

 

On April 8, 2020, the Reporting Persons sold 26,220 shares of Common Stock at a weighted average price of $0.37 per share (price range: $0.33 $0.39).

 

4

 

CUSIP No. 0087A 105

Schedule 13D

 

On April 7, 2020, the Reporting Persons sold 25,152 shares of Common Stock at a weighted average price of $0.33 per share (price range: $0.32 $0.38).

 

On April 6, 2020, the Reporting Persons sold 33,318 shares of Common Stock at a weighted average price of $0.35 per share (price range: $0.32 $0.37).

 

On April 3, 2020, the Reporting Persons sold 28,829 shares of Common Stock at a weighted average price of $0.31 per share (price range: $0.30 $0.38).

 

On April 2, 2020, the Reporting Persons sold 33,396 shares of Common Stock at a weighted average price of $0.32 per share (price range: $0.30 $0.34).

 

On April 1, 2020, the Reporting Persons sold 12,588 shares of Common Stock at a weighted average price of $0.32 per share (price range: $0.31 $0.34).

 

On March 27, 2020, the Reporting Persons sold 6,419 shares of Common Stock at a weighted average price of $0.35 per share (price range: $0.32 $0.38).

 

On March 26, 2020, the Reporting Persons sold 11,448 shares of Common Stock at a weighted average price of $0.38 per share (price range: $0.33 $0.40).

 

On March 25, 2020, the Reporting Persons sold 8,112 shares of Common Stock at a weighted average price of $0.37 per share (price range: $0.35 $0.39).

 

On March 24, 2020, the Reporting Persons sold 6,714 shares of Common Stock at a weighted average price of $0.35 per share (price range: $0.33 $0.36).

 

On March 23, 2020, the Reporting Persons sold 16,932 shares of Common Stock at a weighted average price of $0.32 per share (price range: $0.30 $0.36).

 

On March 20, 2020, the Reporting Persons sold 12,936 shares of Common Stock at a weighted average price of $0.39 per share (price range: $0.36 $0.40).

 

On March 19, 2020, the Reporting Persons sold 8,050 shares of Common Stock at a weighted average price of $0.33 per share (price range: $0.29 $0.38)

 

On March 18, 2020, the Reporting Persons sold 14,221 shares of Common Stock at a weighted average price of $0.30 per share (price range: $0.29 $0.42).

 

On March 17, 2020, the Reporting Persons sold 10,269 shares of Common Stock at a weighted average price of $0.31 per share (price range: $0.29 $0.39).

 

The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Item 5(c).

 

(d)           Not applicable.

 

(e)           Not applicable.

 

Item 6.   Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

 

No changes.

 

Item 7.   Material to be Filed as Exhibits.

 

Exhibit Number		Description
99.1		Agreement regarding joint filing of Schedule 13D

 

 

5

 

CUSIP No. 0087A 105

Schedule 13D

 

Signature

 

After reasonable inquiry and to the best of the undersigneds knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

 

Date:      April 13, 2020

 

	NOVARTIS BIOVENTURES LTD.
	By:	/s/ Bart Dzikowski
	Name:	Bart Dzikowski
	Title:	Secretary of the Board
	By:	/s/ Florian Muellershausen
	Name:	Florian Muellershausen
	Title:	Authorized Signatory
	NOVARTIS AG
	By:	/s/ Bart Dzikowski
	Name:	Bart Dzikowski
	Title:	Authorized Signatory
	By:	/s/ Florian Muellershausen
	Name:	Florian Muellershausen
	Title:	Authorized Signatory

 

6